Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Sarcoma Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

VJVirtual | TCR T-cell therapy shows promise for selected sarcoma subtypes

Javier Martin-Broto, MD, PhD, Fundación Jimenez Diaz University Hospital, Madrid, Spain, comments on the potential of TCR T-cell therapy in sarcomas, highlighting its activity in partial responses, particularly in heavily pretreated patients with synovial sarcoma and myxoid liposarcoma. Dr Martin-Broto suggests that this strategy may be an option for patients with lower tumor burden, but notes that fine-tuning recommendations and considering earlier phases of disease, such as oligometastatic or high-risk localized disease, may be more effective. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.